We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ADE:XETRBitcoin Group SE Analysis

Data as of 2026-05-17 - not real-time

$29.88

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Adeia Inc. (ADE) is trading at $29.88, which sits just below its 20‑day SMA of $30.49 but comfortably above the 50‑day SMA of $27.00, indicating a short‑term pullback within a broader uptrend. The 200‑day SMA at $18.84 underscores a strong long‑term bullish bias. Technical momentum is mixed: the RSI of 52 suggests neutral pressure, while the MACD histogram is negative and the signal line is flagged bearish, hinting at potential near‑term downside. Volume has been increasing, supporting the price move, but the 30‑day volatility of ≈75% signals wide price swings. The stock’s beta of ~2.07 points to heightened sensitivity to market moves, and a max drawdown of ‑34.8% reflects historical risk. Despite these headwinds, the company’s fundamentals—revenue growth of 19.5%, operating margin of 38.9%, and free cash flow of $171.5 M—remain robust.
Valuation metrics show the market is pricing ADE at a P/E of 27, well below the software industry average of 38, and the DCF‑derived fair value of $43 implies an upside of roughly 24%. The dividend yield of 0.67% with a modest payout ratio of 18% appears sustainable given strong cash generation. However, the balance sheet carries a debt‑to‑equity of 85.8%, which, together with the high beta and volatility, elevates the risk profile. Analyst consensus is a strong‑buy with a median target of $37‑$37.5, reinforcing the upside thesis. In summary, the stock is fundamentally sound and undervalued, yet short‑term technical and risk factors warrant a measured approach.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near short‑term support at $26.94
  • Bearish MACD signal suggests near‑term downside
  • Increasing volume provides downside cushion

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervaluation vs DCF fair value of $43
  • Strong revenue growth and high operating margins
  • Analyst consensus strong‑buy with median target ~$37.5

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Sustainable dividend with low payout ratio
  • Robust cash flow and expanding IP licensing franchise
  • Long‑term upside of ~24% to fair value despite current volatility

Key Metrics & Analysis

Financial Health

Revenue Growth19.50%
Profit Margin26.50%
P/E Ratio27.4
ROE28.51%
ROA12.67%
Debt/Equity85.81
P/B Ratio7.1
Op. Cash Flow$159.4M
Free Cash Flow$171.5M
Industry P/E38.6

Technical Analysis

TrendBullish
RSI52.0
Support$26.94
Resistance$34.34
MA 20$30.49
MA 50$27.00
MA 200$18.84
MACDBearish
VolumeIncreasing
Fear & Greed Index88.52

Valuation

Fair Value$43.06
Target Price$37.00
Upside/Downside23.83%
GradeUndervalued
TypeBlend
Dividend Yield0.67%

Risk Assessment

Beta2.08
Volatility75.57%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.